Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
At one year, the drug met its primary and all key secondary endpoints, delivering significantly better weight maintenance than placebo
If cleared by regulators, CagriSema would become the first treatment to combine a GLP-1 receptor agonist and a long-acting amylin analogue in a single injection
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
All pending litigation between Biocon Biologics, Regeneron, and Bayer will be dismissed
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
WINREVAIR is currently the first and only activin signalling inhibitor approved for PAH across all 27 EU member states
Subscribe To Our Newsletter & Stay Updated
